相关实验视频

Updated: Feb 19, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

因子VIII体外生物等价性通过血栓生成试验测定denecimig (Mim8) 血静效应

Jacob Lund¹, Mirella Ezban¹, Kasper Jensen²

¹Rare Blood Disorders, Global Research, Novo Nordisk A/S, Bagsværd, Denmark.

Research and practice in thrombosis and haemostasis

|February 18, 2026

概括

德尼西米格是一种双特异性抗体,在血友病A模型中显示出更高的体外FVIII生物等价性,而不是埃米齐祖马布. 这表明denecimig可能提供有效的静血覆盖,尽管需要进一步的研究.

科学领域:

血液学血液学血液学
药理学药理学是一个学科.
生物化学生物化学

背景情况:

德尼西米格是一种新型双特异性抗体,旨在模仿激活的第八因子 (FVIII),用于治疗A型血友病.
像德尼西米格和埃米齐祖马布这样的FVIII模仿剂的静血疗效需要进一步阐明.

研究的目的:

为了评估denecimig的血液静止活动的体外FVIII生物等价性.
使用血栓生成试验 (TGA) 来比较denecimig和emicizumab.

主要方法:

在各种条件下,在严重的血友病A血中评估了血红素生成.
血中添加了FVIII,denecimig (5μg/mL) 或emicizumab (50μg/mL),并用组织因子 (TF),激活的FXI或激活的FIX触发.

主要成果:

与使用1 pM TF触发器和峰值血栓的埃米齐祖马布 (14 IU/dL) 相比,登西米格显示出更高的FVIII生物等价性 (42 IU/dL).
生物等价性因TGA参数和触发度而异,通常随着触发水平的降低而增加.
在有限的激活FIX条件下,Denecimig表现出高于埃米齐祖马布的高血栓峰值,这表明不同的机制.

结论:

通过TGA进行体外FVIII生物等价性估计取决于检测参数和触发因素.
与埃米齐祖马布-SIA相比,Denecimig在体外显示出更高的FVIII生物等价性.
进一步的研究是有必要的,以充分理解双特异性抗体的血静效应,如Denecimig.

关键词:

生物等价性生物等价性两种特异性的抗体.第八个因子的因素.血友病 (hemophilia) 是一种血友病.血栓激素血栓激素是一种

更多相关视频

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

相关概念视频

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...